# Shouyao Holdings (Beijing)Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shouyao-holdings-beijing-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.shouyaoholding.com
- Total disclosed funding: $29M
- Latest round: Series A (Jul 9, 2019)
- Investors on record: 1

## About

Established in 2016 and based in Beijing, China, Shouyao Holdings (Beijing)Co., LTD previously known as Shouyao Holdings is a biotechnology company that focused on the development and production of new drugs for cancer and diabetes. The company has a full process innovative drug R&D system integrating drug design, target biology, clinical medicine, and translational medicine. The company has 159 invention patents and 22 pipelines of new drugs under investigation. In March 2022, the company was listed on Shanghai Stock Exchange under the number 688197.

The company provides small molecule new drugs for cancer and diabetes. Specific drugs pipeline include SY-707, SY-1530, SY-3505, SY-5007, SY-4835. The SY-707 is an Anaplastic lymphoma kinase inhibitor cured for lung cancer, which is in phase II clinical trials. SY-1530 is in phase II clinical trials for lymphoma indication. SY-707, SY-1530 have been supported by the projects of Major New Drug Creation. SY-5007 is RE arranged during Transfection (RET)inhibitor. SY-4835 is a Wee1 inhibitor. As of March 2022, the company developed drugs all in clinical trials, not in the listing.

The company plans to use IPO funding to R&D of new drugs and build new drugs R&D and industrialization bases.

## Funding rounds

- Series A, Jul 9, 2019, $29M — E-Town International Industrial Investment

## Investors

- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series A